Hunter Shkolnik discute de l'offre de $23 milliards de Teva

novembre 7, 2019

Source: Lecteur juridique

Teva Pharmaceutical Industries Ltd.’s proposed $23 billion drug giveaway over it’s suggesting to settle the opioid lawsuits against it will likely cost the company a fraction of that figure, according to industry experts. When Teva announced the value of the donated medicine – a generic version of opioid addiction treatment Suboxone – it based the figure on the drug’s list price, which does not account for significant discounts it will receive.
Télécharger

Plus de publications

Lecteur juridique

Nos emplacements

S'il vous plaît Nous contacter pour un rendez-vous en personne